Evidence map›Paper›PMID 41767028›Full record

ArticleCJC pediatric and congenital heart disease2026

To Live Long and Prosper: The Final Frontier for Adults With Congenital Heart Disease.

Marnina B Stimmel, Ariela R Orkaby, Fred Ming-Chieh Wu

Abstract readEditorial
In one paragraph

Article in CJC pediatric and congenital heart disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Marnina B StimmelDepartment of Neurology, Montefiore Medical Center, Bronx, New York, USA.
Ariela R OrkabyNew England GRECC, VA Boston Healthcare System, Boston, Massachusetts, USA.
Fred Ming-Chieh WuDepartment of Cardiology, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, USA.

Funding

PREVENTABLE Vanguard PhaseU19AG065188 · NIA · DUKE UNIVERSITY · PI KAREN P ALEXANDER, WALTER T AMBROSIUS · 2019 to 2026
$96.2M
TUFTS--FIELDINGP30AG031679 · NIA · BRIGHAM AND WOMEN'S HOSPITAL · PI SHALENDER BHASIN · 2008 to 2026
$23.9M
The PREVENTABLE Physical Performance Ancillary StudyR01AG071807 · NIA · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI HOUSTON, DENISE KATHRYN · 2021 to 2024
$3.0M
PREVENTABLE Frailty Ancillary StudyR01AG081287 · NIA · BOSTON VA RESEARCH INSTITUTE, INC. · PI ORKABY, ARIELA R · 2024 to 2025
$2.6M
NIA NIH HHS P30 AG031679NIA NIH HHS R01 AG071807NIA NIH HHS R01 AG081287NIA NIH HHS U19 AG065188
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID41767028
PMCPMC12946911

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.